| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA | 26 | 2020 | 227 | 4.450 |
Why?
|
| Fluorodeoxyuridylate | 16 | 2018 | 23 | 4.410 |
Why?
|
| Antineoplastic Agents | 17 | 2019 | 607 | 2.680 |
Why?
|
| Zinc | 7 | 2017 | 32 | 2.120 |
Why?
|
| Fluorouracil | 13 | 2020 | 82 | 2.060 |
Why?
|
| Antimetabolites, Antineoplastic | 13 | 2020 | 49 | 1.990 |
Why?
|
| Nucleic Acid Conformation | 23 | 2017 | 48 | 1.960 |
Why?
|
| Floxuridine | 5 | 2017 | 5 | 1.830 |
Why?
|
| Thymidylate Synthase | 11 | 2020 | 14 | 1.700 |
Why?
|
| Pyrimidines | 3 | 2020 | 65 | 1.690 |
Why?
|
| DNA Topoisomerases, Type I | 4 | 2016 | 9 | 1.450 |
Why?
|
| Apoptosis | 8 | 2017 | 354 | 1.310 |
Why?
|
| DNA Replication | 7 | 2018 | 34 | 1.290 |
Why?
|
| Magnetic Resonance Spectroscopy | 21 | 2014 | 82 | 1.270 |
Why?
|
| Models, Molecular | 22 | 2017 | 193 | 1.130 |
Why?
|
| RNA, Small Nuclear | 6 | 2002 | 6 | 1.100 |
Why?
|
| Oligodeoxyribonucleotides | 8 | 2005 | 17 | 1.030 |
Why?
|
| Polymers | 2 | 2016 | 63 | 0.990 |
Why?
|
| Cell Line, Tumor | 12 | 2019 | 725 | 0.970 |
Why?
|
| Neoplasms | 5 | 2018 | 692 | 0.950 |
Why?
|
| Molecular Dynamics Simulation | 7 | 2017 | 14 | 0.910 |
Why?
|
| DNA Damage | 5 | 2019 | 98 | 0.880 |
Why?
|
| Cell Death | 4 | 2016 | 77 | 0.810 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 12 | 2017 | 20 | 0.800 |
Why?
|
| Prostatic Neoplasms | 3 | 2016 | 470 | 0.790 |
Why?
|
| DNA Repair | 4 | 2016 | 64 | 0.790 |
Why?
|
| Enzyme Inhibitors | 7 | 2012 | 164 | 0.780 |
Why?
|
| src Homology Domains | 11 | 2001 | 13 | 0.770 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 200 | 0.760 |
Why?
|
| Fluorine Compounds | 1 | 2020 | 1 | 0.740 |
Why?
|
| Humans | 52 | 2020 | 31836 | 0.740 |
Why?
|
| Cytarabine | 5 | 2013 | 55 | 0.730 |
Why?
|
| RNA | 8 | 2020 | 91 | 0.720 |
Why?
|
| Colonic Neoplasms | 3 | 2008 | 71 | 0.720 |
Why?
|
| Base Sequence | 18 | 2005 | 251 | 0.710 |
Why?
|
| Ethylenediamines | 2 | 2016 | 6 | 0.670 |
Why?
|
| Chelating Agents | 2 | 2016 | 17 | 0.670 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 2016 | 10 | 0.670 |
Why?
|
| Thymine | 2 | 2016 | 6 | 0.660 |
Why?
|
| Protein-Tyrosine Kinases | 9 | 2000 | 40 | 0.660 |
Why?
|
| Drug Delivery Systems | 3 | 2016 | 104 | 0.660 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2000 | 85 | 0.640 |
Why?
|
| Oligonucleotides | 5 | 2014 | 30 | 0.630 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 85 | 0.630 |
Why?
|
| Netropsin | 2 | 2012 | 3 | 0.620 |
Why?
|
| Curcumin | 1 | 2017 | 7 | 0.610 |
Why?
|
| Anticarcinogenic Agents | 1 | 2017 | 23 | 0.600 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 37 | 0.590 |
Why?
|
| Mice | 13 | 2018 | 2476 | 0.570 |
Why?
|
| Thermodynamics | 15 | 2017 | 46 | 0.530 |
Why?
|
| Animals | 18 | 2018 | 7450 | 0.510 |
Why?
|
| Deoxycytidine | 4 | 2003 | 68 | 0.510 |
Why?
|
| Fas Ligand Protein | 2 | 2014 | 7 | 0.510 |
Why?
|
| Binding Sites | 10 | 2017 | 130 | 0.500 |
Why?
|
| Water | 6 | 2009 | 56 | 0.500 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 148 | 0.500 |
Why?
|
| Membrane Microdomains | 1 | 2014 | 21 | 0.490 |
Why?
|
| Colorectal Neoplasms | 4 | 2019 | 216 | 0.480 |
Why?
|
| Prodrugs | 5 | 2002 | 16 | 0.480 |
Why?
|
| Molecular Sequence Data | 17 | 2002 | 355 | 0.480 |
Why?
|
| DNA, Single-Stranded | 2 | 2013 | 13 | 0.470 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 66 | 0.470 |
Why?
|
| Peptides | 4 | 2001 | 119 | 0.470 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 44 | 0.470 |
Why?
|
| Doxorubicin | 1 | 2014 | 82 | 0.450 |
Why?
|
| Porphyrins | 1 | 2013 | 29 | 0.450 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 74 | 0.450 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 3 | 2002 | 4 | 0.440 |
Why?
|
| Tumor Cells, Cultured | 9 | 2012 | 168 | 0.430 |
Why?
|
| Coordination Complexes | 1 | 2012 | 9 | 0.430 |
Why?
|
| Proteins | 3 | 2001 | 144 | 0.430 |
Why?
|
| Zinc Fingers | 3 | 2017 | 9 | 0.420 |
Why?
|
| Circular Dichroism | 6 | 2017 | 30 | 0.420 |
Why?
|
| Glioblastoma | 1 | 2013 | 156 | 0.400 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 323 | 0.400 |
Why?
|
| Drug Synergism | 4 | 2019 | 66 | 0.400 |
Why?
|
| Amino Acid Sequence | 11 | 2017 | 283 | 0.390 |
Why?
|
| Drug Screening Assays, Antitumor | 6 | 2019 | 58 | 0.380 |
Why?
|
| DNA, Viral | 3 | 1999 | 52 | 0.380 |
Why?
|
| Distamycins | 2 | 2000 | 2 | 0.360 |
Why?
|
| RNA, Messenger | 4 | 2010 | 508 | 0.360 |
Why?
|
| Genome, Human | 1 | 2010 | 132 | 0.350 |
Why?
|
| Hydrogen Bonding | 8 | 2017 | 22 | 0.350 |
Why?
|
| Protein Structure, Secondary | 6 | 2017 | 47 | 0.350 |
Why?
|
| Structure-Activity Relationship | 5 | 2020 | 80 | 0.350 |
Why?
|
| Nanotubes, Carbon | 1 | 2009 | 23 | 0.340 |
Why?
|
| Spectrophotometry, Ultraviolet | 6 | 2017 | 18 | 0.340 |
Why?
|
| Hot Temperature | 1 | 2009 | 70 | 0.340 |
Why?
|
| Protein Conformation | 8 | 2015 | 84 | 0.340 |
Why?
|
| Laser Therapy | 1 | 2009 | 55 | 0.330 |
Why?
|
| Drug Design | 4 | 2005 | 43 | 0.330 |
Why?
|
| Nucleosides | 2 | 2010 | 10 | 0.320 |
Why?
|
| MicroRNAs | 1 | 2010 | 180 | 0.310 |
Why?
|
| Gene Expression | 2 | 2017 | 334 | 0.310 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 638 | 0.300 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 77 | 0.300 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 760 | 0.290 |
Why?
|
| RNA, Double-Stranded | 2 | 1997 | 6 | 0.290 |
Why?
|
| Protons | 6 | 2005 | 23 | 0.290 |
Why?
|
| Adenocarcinoma | 2 | 2008 | 311 | 0.280 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 221 | 0.280 |
Why?
|
| Protein Binding | 7 | 2017 | 201 | 0.280 |
Why?
|
| I-kappa B Kinase | 2 | 2017 | 8 | 0.270 |
Why?
|
| Mice, Nude | 3 | 2013 | 290 | 0.260 |
Why?
|
| Aptamers, Nucleotide | 3 | 2016 | 10 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 114 | 0.250 |
Why?
|
| Simian virus 40 | 3 | 1999 | 4 | 0.250 |
Why?
|
| Uracil | 2 | 2002 | 6 | 0.240 |
Why?
|
| Strontium | 1 | 2004 | 5 | 0.240 |
Why?
|
| Bacteriophage Pf1 | 1 | 2004 | 1 | 0.240 |
Why?
|
| HL-60 Cells | 2 | 2014 | 14 | 0.230 |
Why?
|
| Protein Folding | 7 | 2017 | 29 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 104 | 0.220 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 29 | 0.210 |
Why?
|
| Ribonucleoprotein, U4-U6 Small Nuclear | 1 | 2002 | 1 | 0.210 |
Why?
|
| DNA, Neoplasm | 3 | 2012 | 55 | 0.210 |
Why?
|
| Temperature | 4 | 2005 | 53 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-hck | 9 | 2000 | 9 | 0.200 |
Why?
|
| Computer Simulation | 4 | 2012 | 220 | 0.200 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2001 | 2 | 0.200 |
Why?
|
| Folic Acid | 1 | 2001 | 12 | 0.200 |
Why?
|
| Membrane Transport Proteins | 1 | 2001 | 34 | 0.190 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 70 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 261 | 0.190 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2001 | 3 | 0.190 |
Why?
|
| Chemical Phenomena | 1 | 2020 | 3 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 766 | 0.180 |
Why?
|
| Ethidium | 1 | 2000 | 1 | 0.180 |
Why?
|
| Uridine | 2 | 2000 | 3 | 0.180 |
Why?
|
| Phthalazines | 1 | 2019 | 4 | 0.170 |
Why?
|
| Pyrazines | 1 | 2019 | 13 | 0.170 |
Why?
|
| Cell Division | 1 | 1999 | 95 | 0.170 |
Why?
|
| Piperazines | 1 | 2019 | 54 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2019 | 67 | 0.170 |
Why?
|
| Neoplasm Transplantation | 2 | 2013 | 73 | 0.160 |
Why?
|
| Stress, Physiological | 1 | 2018 | 55 | 0.160 |
Why?
|
| Phosphopeptides | 1 | 1998 | 3 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 168 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2009 | 57 | 0.160 |
Why?
|
| Solutions | 4 | 2004 | 35 | 0.160 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 16 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 5 | 2001 | 99 | 0.150 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2017 | 27 | 0.150 |
Why?
|
| Disease | 1 | 2017 | 5 | 0.150 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 59 | 0.150 |
Why?
|
| Deoxyuridine | 2 | 2017 | 2 | 0.150 |
Why?
|
| Ligands | 4 | 2001 | 80 | 0.150 |
Why?
|
| Magnesium | 1 | 2017 | 30 | 0.150 |
Why?
|
| Amides | 2 | 1997 | 18 | 0.150 |
Why?
|
| Substrate Specificity | 2 | 2012 | 86 | 0.150 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 90 | 0.150 |
Why?
|
| Molecular Structure | 5 | 2007 | 59 | 0.150 |
Why?
|
| Cations, Divalent | 2 | 2017 | 4 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 23 | 0.140 |
Why?
|
| DNA Breaks, Single-Stranded | 1 | 2016 | 1 | 0.140 |
Why?
|
| Quantum Theory | 1 | 1996 | 1 | 0.140 |
Why?
|
| Folic Acid Antagonists | 2 | 2007 | 3 | 0.140 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2016 | 7 | 0.140 |
Why?
|
| Antigens, Surface | 1 | 2016 | 24 | 0.140 |
Why?
|
| Base Composition | 4 | 1998 | 10 | 0.140 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1996 | 48 | 0.140 |
Why?
|
| Liposomes | 1 | 2016 | 27 | 0.140 |
Why?
|
| Male | 5 | 2016 | 19091 | 0.130 |
Why?
|
| Prostate | 1 | 2016 | 67 | 0.130 |
Why?
|
| Female | 5 | 2019 | 19859 | 0.130 |
Why?
|
| Guanine | 3 | 2007 | 15 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 20 | 0.120 |
Why?
|
| Hydrogen | 4 | 2001 | 8 | 0.120 |
Why?
|
| Cells, Cultured | 2 | 2013 | 833 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2016 | 229 | 0.120 |
Why?
|
| Caspases | 1 | 2013 | 38 | 0.120 |
Why?
|
| Stearic Acids | 1 | 2013 | 5 | 0.110 |
Why?
|
| Endosomes | 1 | 2013 | 12 | 0.110 |
Why?
|
| Static Electricity | 3 | 2002 | 11 | 0.110 |
Why?
|
| Lipid Peroxidation | 1 | 2013 | 32 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 629 | 0.110 |
Why?
|
| Nanomedicine | 1 | 2013 | 16 | 0.110 |
Why?
|
| Oligoribonucleotides | 3 | 1998 | 3 | 0.110 |
Why?
|
| Photosensitizing Agents | 1 | 2013 | 23 | 0.110 |
Why?
|
| Cell Membrane | 1 | 2013 | 96 | 0.110 |
Why?
|
| Camptothecin | 2 | 2010 | 52 | 0.110 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2012 | 2 | 0.110 |
Why?
|
| Cytotoxins | 1 | 2012 | 13 | 0.110 |
Why?
|
| S Phase | 1 | 2012 | 15 | 0.110 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2012 | 17 | 0.110 |
Why?
|
| Alkaloids | 1 | 2012 | 9 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 156 | 0.110 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2012 | 21 | 0.110 |
Why?
|
| Ions | 2 | 2017 | 12 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2013 | 108 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2013 | 125 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 114 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 22 | 0.100 |
Why?
|
| Endoribonucleases | 1 | 1990 | 4 | 0.090 |
Why?
|
| Topotecan | 1 | 2010 | 17 | 0.090 |
Why?
|
| Neurons | 2 | 2013 | 409 | 0.090 |
Why?
|
| Endocytosis | 1 | 2010 | 10 | 0.090 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 19 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1990 | 30 | 0.090 |
Why?
|
| Diffusion | 2 | 2001 | 13 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 192 | 0.090 |
Why?
|
| Intercalating Agents | 2 | 2002 | 9 | 0.090 |
Why?
|
| Time Factors | 2 | 2013 | 2146 | 0.090 |
Why?
|
| Solubility | 1 | 2009 | 37 | 0.090 |
Why?
|
| G-Quadruplexes | 2 | 2006 | 8 | 0.080 |
Why?
|
| Peptide Fragments | 4 | 1999 | 398 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2009 | 291 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2008 | 18 | 0.080 |
Why?
|
| Complement System Proteins | 1 | 2008 | 10 | 0.080 |
Why?
|
| Calorimetry, Differential Scanning | 3 | 2006 | 12 | 0.080 |
Why?
|
| Nucleic Acid Denaturation | 2 | 1998 | 5 | 0.080 |
Why?
|
| Models, Chemical | 2 | 2005 | 34 | 0.080 |
Why?
|
| Mass Spectrometry | 4 | 2001 | 103 | 0.080 |
Why?
|
| Cell Line | 3 | 2013 | 434 | 0.080 |
Why?
|
| Principal Component Analysis | 2 | 2017 | 68 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 161 | 0.070 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 27 | 0.070 |
Why?
|
| Aspartic Acid | 2 | 1996 | 12 | 0.060 |
Why?
|
| Imines | 1 | 2005 | 2 | 0.060 |
Why?
|
| Catalysis | 1 | 2005 | 65 | 0.060 |
Why?
|
| Thrombin | 1 | 2004 | 15 | 0.060 |
Why?
|
| Oxygen Isotopes | 1 | 2004 | 7 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 2004 | 21 | 0.060 |
Why?
|
| HT29 Cells | 1 | 2004 | 4 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2012 | 3294 | 0.060 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2004 | 30 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2001 | 85 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2002 | 20 | 0.050 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 2002 | 1 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2002 | 8 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2002 | 93 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2002 | 122 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 78 | 0.050 |
Why?
|
| Colon | 1 | 2002 | 51 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2002 | 40 | 0.050 |
Why?
|
| Hela Cells | 1 | 2002 | 78 | 0.050 |
Why?
|
| United States | 1 | 2010 | 3925 | 0.050 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2001 | 1 | 0.050 |
Why?
|
| snRNP Core Proteins | 1 | 2001 | 1 | 0.050 |
Why?
|
| Molecular Conformation | 1 | 2001 | 12 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2001 | 33 | 0.050 |
Why?
|
| Autoantigens | 1 | 2001 | 16 | 0.050 |
Why?
|
| Glycine | 1 | 2001 | 27 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 24 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 68 | 0.050 |
Why?
|
| Cattle | 1 | 2001 | 103 | 0.050 |
Why?
|
| Drug Stability | 2 | 2002 | 8 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2001 | 137 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 103 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 1997 | 247 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2000 | 31 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2001 | 257 | 0.040 |
Why?
|
| Rad51 Recombinase | 1 | 2019 | 3 | 0.040 |
Why?
|
| Orotate Phosphoribosyltransferase | 1 | 1999 | 1 | 0.040 |
Why?
|
| Biotransformation | 1 | 1999 | 4 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 10 | 0.040 |
Why?
|
| Thymidine Kinase | 1 | 1999 | 5 | 0.040 |
Why?
|
| Lethal Dose 50 | 1 | 1999 | 4 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 137 | 0.040 |
Why?
|
| Half-Life | 1 | 1999 | 22 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1999 | 94 | 0.040 |
Why?
|
| Genome, Viral | 1 | 1999 | 10 | 0.040 |
Why?
|
| Fibroblasts | 1 | 1999 | 112 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 1998 | 17 | 0.040 |
Why?
|
| Cell Survival | 1 | 2019 | 286 | 0.040 |
Why?
|
| Hydrogels | 1 | 2019 | 121 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 70 | 0.040 |
Why?
|
| Chickens | 2 | 2013 | 38 | 0.040 |
Why?
|
| Markov Chains | 1 | 2017 | 29 | 0.040 |
Why?
|
| Body Weight | 1 | 1999 | 306 | 0.040 |
Why?
|
| Motion | 1 | 1997 | 11 | 0.040 |
Why?
|
| Cytosine | 1 | 1997 | 10 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 128 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2001 | 687 | 0.040 |
Why?
|
| Nuclear Physics | 1 | 1996 | 1 | 0.030 |
Why?
|
| Quinazolines | 2 | 2007 | 38 | 0.030 |
Why?
|
| Thiophenes | 2 | 2007 | 23 | 0.030 |
Why?
|
| Lysine | 1 | 1996 | 23 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 1995 | 13 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 304 | 0.030 |
Why?
|
| Algorithms | 1 | 1999 | 495 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 764 | 0.030 |
Why?
|
| AIDS Dementia Complex | 1 | 1994 | 2 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 404 | 0.030 |
Why?
|
| Zalcitabine | 1 | 2013 | 1 | 0.030 |
Why?
|
| Zidovudine | 1 | 2013 | 2 | 0.030 |
Why?
|
| Acyclovir | 1 | 2013 | 13 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 66 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 655 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2013 | 34 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 55 | 0.030 |
Why?
|
| Transfection | 1 | 2013 | 191 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2013 | 108 | 0.030 |
Why?
|
| Deoxyribonucleosides | 1 | 1990 | 1 | 0.020 |
Why?
|
| Carbohydrate Conformation | 1 | 1990 | 2 | 0.020 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1990 | 4 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 1990 | 9 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 18 | 0.020 |
Why?
|
| Ribonuclease H | 1 | 1990 | 7 | 0.020 |
Why?
|
| Crystallography, X-Ray | 2 | 2000 | 90 | 0.020 |
Why?
|
| Glutamates | 1 | 2007 | 11 | 0.020 |
Why?
|
| Potassium | 1 | 2006 | 38 | 0.020 |
Why?
|
| Leukemia P388 | 1 | 2005 | 2 | 0.020 |
Why?
|
| Thymidine | 1 | 2005 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 34 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2000 | 77 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 102 | 0.010 |
Why?
|
| Deuterium | 1 | 1999 | 9 | 0.010 |
Why?
|
| Gene Products, nef | 1 | 1997 | 1 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 1997 | 1 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 1997 | 11 | 0.010 |
Why?
|
| Pepsin A | 1 | 1997 | 8 | 0.010 |
Why?
|
| HIV | 1 | 1997 | 24 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 75 | 0.010 |
Why?
|
| Proline | 1 | 1995 | 12 | 0.010 |
Why?
|
| Creatine | 1 | 1994 | 5 | 0.010 |
Why?
|
| Choline | 1 | 1994 | 14 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1994 | 2277 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1994 | 1323 | 0.000 |
Why?
|
| Child | 1 | 1994 | 2425 | 0.000 |
Why?
|
| Adult | 1 | 1994 | 9327 | 0.000 |
Why?
|
| Middle Aged | 1 | 1994 | 11824 | 0.000 |
Why?
|